Ranked by interpretable importance, issuer history, magnitude, and accounting profile. No directional recommendation.
Shares outstanding changed -81.1% from the comparable as-filed period. The change ranks at the 29th percentile of 7 prior comparable changes. This reverses 4 consecutive comparable moves in the opposite direction.
Operating cash flow changed -36.1% from the comparable as-filed period.
Cash & equivalents changed -59.7% from the comparable as-filed period.
Working capital changed -55.1% from the comparable as-filed period.
Operating income changed +19.0% from the comparable as-filed period.
Current assets changed -55.8% from the comparable as-filed period.
Total assets changed -55.8% from the comparable as-filed period.
Current liabilities changed -58.4% from the comparable as-filed period.
Stock-based compensation changed -99.5% from the comparable as-filed period.
Working capital / assets changed +110 basis points from the comparable as-filed period. This reverses 3 consecutive comparable moves in the opposite direction.
Research & development changed -4.9% from the comparable as-filed period. This reverses 3 consecutive comparable moves in the opposite direction.
Current ratio changed +6.1% from the comparable as-filed period. This reverses 3 consecutive comparable moves in the opposite direction.
Revenue changed from 0 to 0 USD in the comparable as-filed period. Relative percentage is de-emphasized because the comparison has a zero base.
Method Importance combines metric-family relevance, magnitude, issuer-history unusualness, persistence, and financial-statement significance. It is analytical prioritization, not a legal materiality conclusion or investment signal.